Literature DB >> 12943027

Cognitive predictors of symptom return following depression treatment.

Christopher G Beevers1, Gabor I Keitner, Christine E Ryan, Ivan W Miller.   

Abstract

This study tested whether poor cognitive change during depression treatment predicted time to return of depressive symptoms. Depressed participants (N = 121) completed assessments of dysfunctional attitudes and extreme thinking (i.e., number of totally agree and totally disagree responses) during hospitalization and again after 6 months of outpatient treatment. Participants then completed monthly depression assessments for 1 year. Survival analyses for time to symptom recurrence during follow-up were conducted among participants who reported 50% improvement in their depressive symptoms and were at least partially asymptomatic at the end of treatment (n = 53). Poor change in dysfunctional attitudes and poor change in extreme thinking both predicted shorter time to return of depressive symptoms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12943027     DOI: 10.1037/0021-843x.112.3.488

Source DB:  PubMed          Journal:  J Abnorm Psychol        ISSN: 0021-843X


  9 in total

1.  Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up.

Authors:  Robin B Jarrett; Michael E Thase
Journal:  Contemp Clin Trials       Date:  2010-05-06       Impact factor: 2.226

2.  Extreme cognitions in bipolar spectrum disorders: associations with personality disorder characteristics and risk for episode recurrence.

Authors:  Jonathan P Stange; Ashleigh Molz Adams; Jared K O'Garro-Moore; Rachel B Weiss; Mian-Li Ong; Patricia D Walshaw; Lyn Y Abramson; Lauren B Alloy
Journal:  Behav Ther       Date:  2014-09-19

3.  An examination of dysfunctional attitudes and extreme response styles as predictors of relapse in guided internet-based cognitive behavioral therapy for depression.

Authors:  Iony D Ezawa; Nicholas R Forand; Daniel R Strunk
Journal:  J Clin Psychol       Date:  2020-04-21

4.  Extreme attributions predict transition from depression to mania or hypomania in bipolar disorder.

Authors:  Jonathan P Stange; Louisa G Sylvia; Pedro Vieira da Silva Magalhães; Ellen Frank; Michael W Otto; David J Miklowitz; Michael Berk; Andrew A Nierenberg; Thilo Deckersbach
Journal:  J Psychiatr Res       Date:  2013-06-21       Impact factor: 4.791

5.  Extreme thinking in clinically depressed adolescents: Results from the Treatment for Adolescents with Depression Study (TADS).

Authors:  Rachel H Jacobs; Mark A Reinecke; Jackie K Gollan; Neil Jordan; Susan G Silva; John S March
Journal:  Behav Res Ther       Date:  2010-08-11

6.  Changes in cognitive content during and following cognitive therapy for recurrent depression: substantial and enduring, but not predictive of change in depressive symptoms.

Authors:  Robin B Jarrett; Jeffrey R Vittengl; Kimberly Doyle; Lee Anna Clark
Journal:  J Consult Clin Psychol       Date:  2007-06

7.  Extreme attributions predict the course of bipolar depression: results from the STEP-BD randomized controlled trial of psychosocial treatment.

Authors:  Jonathan P Stange; Louisa G Sylvia; Pedro Vieira da Silva Magalhães; David J Miklowitz; Michael W Otto; Ellen Frank; Michael Berk; Andrew A Nierenberg; Thilo Deckersbach
Journal:  J Clin Psychiatry       Date:  2013-03       Impact factor: 4.384

8.  Acceptance and Commitment Therapy for Inpatients with Psychosis (the REACH Study): Protocol for Treatment Development and Pilot Testing.

Authors:  Brandon A Gaudiano; Carter H Davis; Gary Epstein-Lubow; Jennifer E Johnson; Kim T Mueser; Ivan W Miller
Journal:  Healthcare (Basel)       Date:  2017-05-05

9.  Understanding the paranoid psychosis of James: Use of the repertory grid technique for case conceptualization.

Authors:  Helena García-Mieres; Susana Ochoa; Marta Salla; Raquel López-Carrilero; Guillem Feixas
Journal:  World J Psychiatry       Date:  2016-09-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.